title: Combination of paclitaxel thermal gel depot with temozolomide and radiotherapy significantly prolongs survival in an experimental rodent glioma model.
abstract: OncoGel™ incorporates paclitaxel, a mitotic inhibitor, into ReGel™, a thermosensitive gel depot system to provide local delivery, enhance efficacy and limit systemic toxicity. In previous studies the alkylating agent temozolomide (TMZ) incorporated into a polymer, pCPP:SA, also for local delivery, and OncoGel were individually shown to increase efficacy in a rat glioma model. We investigated the effects of OncoGel with oral TMZ or locally delivered TMZ polymer, with and without radiotherapy (XRT) in rats with intracranial gliosarcoma. Eighty-nine animals were intracranially implanted with a 9L gliosarcoma tumor and divided into 12 groups that received various combinations of 4 treatment options; OncoGel 6.3 mg/ml (Day 0), 20 Gy XRT (Day 5), 50 % TMZ-pCPP:SA (Day 5), or oral TMZ (50 mg/kg, qd, Days 5-9). Animals were followed for survival for 120 days. Median survival for untreated controls, XRT alone or oral TMZ alone was 15, 19 and 28 days, respectively. OncoGel 6.3 or TMZ polymer alone extended median survival to 33 and 35 days, respectively (p = 0.0005; p < 0.0001, vs. untreated controls) with 50 % living greater than 120 days (LTS) in both groups. Oral TMZ/XRT extended median survival to 36 days (p = 0.0002), with no LTS. The group that received OncoGel and Oral TMZ did not reach median survival with 57 % LTS (p = 0.0002). All other combination groups [OncoGel/XRT], [TMZ polymer/XRT], [OncoGel/TMZ polymer], [OncoGel/TMZ polymer/XRT], and [OncoGel/oral TMZ/XRT] yielded greater than 50 % LTS (p < 0.0001 for each combination as compared to controls), therefore median survival was not reached. OncoGel/TMZ polymer and OncoGel/oral TMZ/XRT had 100 % LTS (p < 0.0001 and p = 0.0001 vs. oral TMZ/XRT, respectively). These results indicate that OncoGel given locally with oral or locally delivered TMZ and/or XRT significantly increased the number of LTS and improved median survival compared to oral TMZ and XRT given alone or in combination in a rodent intracranial gliosarcoma model.
authors.affiliation: Department of Neurosurgery, Johns Hopkins University School of Medicine, 1550 Orleans Street CRB2 2M41, Baltimore, MD 21231, USA.
authors.forename: Ananth K
authors.initials: AK
authors.lastname: Vellimana
authors.forename: Violette Renard
authors.initials: VR
authors.lastname: Recinos
authors.forename: Lee
authors.initials: L
authors.lastname: Hwang
authors.forename: Kirk D
authors.initials: KD
authors.lastname: Fowers
authors.forename: Khan W
authors.initials: KW
authors.lastname: Li
authors.forename: Yonggang
authors.initials: Y
authors.lastname: Zhang
authors.forename: Saint
authors.initials: S
authors.lastname: Okonma
authors.forename: Charles G
authors.initials: CG
authors.lastname: Eberhart
authors.forename: Henry
authors.initials: H
authors.lastname: Brem
authors.forename: Betty M
authors.initials: BM
authors.lastname: Tyler
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004195:Disease Models, Animal; D016503:Drug Delivery Systems / Q000379:methods; D004359:Drug Therapy, Combination; D005260:Female; D005782:Gels / Q000627:therapeutic use; D005910:Glioma / Q000188:drug therapy* / Q000532:radiotherapy*; D006801:Humans; D009368:Neoplasm Transplantation; D017239:Paclitaxel / Q000627:therapeutic use*; D051381:Rats; D011916:Rats, Inbred F344; D016019:Survival Analysis; D000077204:Temozolomide
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D005782:Gels; D003606:Dacarbazine; D017239:Paclitaxel; D000077204:Temozolomide